RIPK3 and cancer: As shown in Fig. 3a–c, various cancer cells (either in the presence or absence of MLKL knockdown) completely lost their sensitivity to TRAIL when treated with the pan-caspase inhibitor zVAD; lack of necroptotic cell death is consistent with the fact that these cells lack RIP3 expression.